On the contrary, the standard arm follows a regular diet, with a total of 602 patients expected to be included and a primary endpoint of disease-free survival at 3 years (NCT05384444)
In a 2023 study, BPC-157 significantly sped up healing of rats intestinal lining, supporting its proposed effects on gut health
Triple-receptor agonist, GLP-1, GIP, and glucagon pathways Extended half-life for stable pharmacokinetic profiles Subject of multiple ongoing clinical trials Pre-filled pen for precise, repeatable delivery Janoshik-verified, 99% purity guaranteed What Researchers Say Frequently Asked Questions Retatrutide (LY3437943) is an investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors
It may be beneficial for patients seeking support for muscles, tendons, ligaments, and overall recovery